Base de dados : MEDLINE
Pesquisa : D27.505.519.625.375.425.400 [Categoria DeCS]
Referências encontradas : 11639 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1164 ir para página                         

  1 / 11639 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28818308
[Au] Autor:Düzenli U; Bozan N; Ayral A; Yalinkiliç A; Kiroglu AF
[Ad] Endereço:Yüzüncü Yil University, Faculty of Medicine, Department of Otorhinolaryngology, Van, Turkey. Electronic address: ufukduzenli@yyu.edu.tr.
[Ti] Título:A honey bee can threat ear: Sudden sensorineural hearing loss.
[So] Source:Am J Emerg Med;35(11):1788.e1-1788.e3, 2017 Nov.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sudden sensorineural hearing loss is an otologic emergency. Many etiological factors can lead to this pathology. Honey bee (Apis mellifera) sting may lead to local and systemic reactions due to sensitization of the patient. In this paper we described a sudden sensorineural hearing loss occurred after honey bee sting.
[Mh] Termos MeSH primário: Perda Auditiva Súbita/etiologia
Hipersensibilidade/etiologia
Mordeduras e Picadas de Insetos/complicações
[Mh] Termos MeSH secundário: Betametasona/uso terapêutico
Dexametasona/uso terapêutico
Dispneia/etiologia
Glucocorticoides/uso terapêutico
Perda Auditiva Súbita/tratamento farmacológico
Perda Auditiva Súbita/fisiopatologia
Testes Auditivos
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Seres Humanos
Hipersensibilidade/tratamento farmacológico
Injeção Intratimpânica
Mordeduras e Picadas de Insetos/tratamento farmacológico
Masculino
Metilprednisolona/uso terapêutico
Náusea/etiologia
Feniramina/uso terapêutico
Zumbido/etiologia
Vômito/etiologia
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Histamine H1 Antagonists); 134FM9ZZ6M (Pheniramine); 7S5I7G3JQL (Dexamethasone); 9842X06Q6M (Betamethasone); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170819
[St] Status:MEDLINE


  2 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28697105
[Au] Autor:Abernathy A; Alsina L; Greer J; Egerman R
[Ad] Endereço:University of Florida College of Medicine, Gainesville, Florida.
[Ti] Título:Transient Fetal Tachycardia After Intravenous Diphenhydramine Administration.
[So] Source:Obstet Gynecol;130(2):374-376, 2017 Aug.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Fetal tachycardia is attributable to a variety of etiologies, including an untreated maternal medical condition or an indicator of potential fetal compromise. Maternal medication administration may also affect the fetal heart rate. CASE: A 28-year-old nulliparous patient at 41 weeks of gestation was treated for pruritus with intravenous diphenhydramine after epidural administration of fentanyl. Within 14 minutes, the fetal heart rate increased from a baseline of 155 beats per minute (bpm) to more than 200 bpm while maintaining moderate variability. This was accompanied by an increase in uterine contractions occurring every 1.5 minutes. The fetal tachycardia lasted 51 minutes; several hours later, a healthy neonate was delivered. CONCLUSION: Diphenhydramine may produce transient fetal tachycardia as well as increased maternal uterine activity.
[Mh] Termos MeSH primário: Difenidramina/efeitos adversos
Doenças Fetais/induzido quimicamente
Frequência Cardíaca Fetal/efeitos dos fármacos
Antagonistas dos Receptores Histamínicos H1/efeitos adversos
Taquicardia/induzido quimicamente
Taquicardia/embriologia
[Mh] Termos MeSH secundário: Administração Intravenosa
Adulto
Analgésicos Opioides
Cesárea
Feminino
Fentanila/efeitos adversos
Idade Gestacional
Seres Humanos
Recém-Nascido
Trabalho de Parto Induzido
Gravidez
Prurido/induzido quimicamente
Prurido/tratamento farmacológico
Contração Uterina/efeitos dos fármacos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Histamine H1 Antagonists); 8GTS82S83M (Diphenhydramine); UF599785JZ (Fentanyl)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002147


  3 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28671445
[Au] Autor:Schaefer P
[Ad] Endereço:University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
[Ti] Título:Acute and Chronic Urticaria: Evaluation and Treatment.
[So] Source:Am Fam Physician;95(11):717-724, 2017 Jun 01.
[Is] ISSN:1532-0650
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Urticaria commonly presents with intensely pruritic wheals, sometimes with edema of the subcutaneous or interstitial tissue. It has a lifetime prevalence of about 20%. Although often self-limited and benign, it can cause significant discomfort, continue for months to years, and uncommonly represent a serious systemic disease or life-threatening allergic reaction. Urticaria is caused by immunoglobulin E- and non-immunoglobulin E-mediated release of histamine and other inflammatory mediators from mast cells and basophils. Diagnosis is made clinically; anaphylaxis must be ruled out. Chronic urticaria is idiopathic in 80% to 90% of cases. Only a limited nonspecific laboratory workup should be considered unless elements of the history or physical examination suggest specific underlying conditions. The mainstay of treatment is avoidance of triggers, if identified. The first-line pharmacotherapy is second-generation H1 antihistamines, which can be titrated to greater than standard doses. First-generation H1 antihistamines, H2 antihistamines, leukotriene receptor antagonists, high-potency antihistamines, and brief corticosteroid bursts may be used as adjunctive treatment. In refractory chronic urticaria, patients can be referred to subspecialists for additional treatments, such as omalizumab or cyclosporine. More than one-half of patients with chronic urticaria will have resolution or improvement of symptoms within a year.
[Mh] Termos MeSH primário: Urticária/diagnóstico
[Mh] Termos MeSH secundário: Ciclosporina/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Diagnóstico Diferencial
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Seres Humanos
Omalizumab/uso terapêutico
Urticária/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Histamine H1 Antagonists); 2P471X1Z11 (Omalizumab); 83HN0GTJ6D (Cyclosporine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE


  4 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28656804
[Au] Autor:Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F
[Ad] Endereço:a Division of Allergy and Clinical Immunology, Department of Medicine , East Tennessee Statement , Johnson City , TN , USA.
[Ti] Título:Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.
[So] Source:Expert Opin Pharmacother;18(11):1137-1143, 2017 Aug.
[Is] ISSN:1744-7666
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Olopatadine hydrochloride is an antihistamine and mast cell stabilizer available as oral, intranasal and ocular preparations. Most of the practical applications of olopatadine therapy focus on the treatment of allergic rhinoconjunctivitis via intranasal and ocular routes. Areas covered: This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of children and adults. The articles that have been selected, evaluate the use of intranasal and ocular antihistamines and their role in allergic rhinoconjunctivitis. Expert opinion: Olopatadine is significantly more effective than placebos in relieving the symptoms of allergic rhinoconjunctivitis. It can function both as a viable alternative or addition to first line therapies such as intranasal steroids and oral antihistamines.
[Mh] Termos MeSH primário: Antialérgicos/uso terapêutico
Conjuntivite Alérgica/tratamento farmacológico
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Cloridrato de Olopatadina/uso terapêutico
[Mh] Termos MeSH secundário: Administração Intranasal
Administração Oftálmica
Administração Oral
Adulto
Antialérgicos/administração & dosagem
Antialérgicos/efeitos adversos
Ensaios Clínicos como Assunto
Antagonistas dos Receptores Histamínicos H1/administração & dosagem
Antagonistas dos Receptores Histamínicos H1/efeitos adversos
Seres Humanos
Cloridrato de Olopatadina/administração & dosagem
Cloridrato de Olopatadina/efeitos adversos
Cloridrato de Olopatadina/farmacocinética
Soluções Oftálmicas/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Histamine H1 Antagonists); 0 (Ophthalmic Solutions); 2XG66W44KF (Olopatadine Hydrochloride)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1080/14656566.2017.1346085


  5 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28602936
[Au] Autor:Brozek JL; Bousquet J; Agache I; Agarwal A; Bachert C; Bosnic-Anticevich S; Brignardello-Petersen R; Canonica GW; Casale T; Chavannes NH; Correia de Sousa J; Cruz AA; Cuello-Garcia CA; Demoly P; Dykewicz M; Etxeandia-Ikobaltzeta I; Florez ID; Fokkens W; Fonseca J; Hellings PW; Klimek L; Kowalski S; Kuna P; Laisaar KT; Larenas-Linnemann DE; Lødrup Carlsen KC; Manning PJ; Meltzer E; Mullol J; Muraro A; O'Hehir R; Ohta K; Panzner P; Papadopoulos N; Park HS; Passalacqua G; Pawankar R; Price D; Riva JJ; Roldán Y; Ryan D; Sadeghirad B; Samolinski B; Schmid-Grendelmeier P; Sheikh A; Togias A; Valero A; Valiulis A; Valovirta E; Ventresca M
[Ad] Endereço:Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: jan.l.brozek@gmail.com.
[Ti] Título:Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.
[So] Source:J Allergy Clin Immunol;140(4):950-958, 2017 Oct.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. OBJECTIVE: We sought to provide a targeted update of the ARIA guidelines. METHODS: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. RESULTS: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H -antihistamines, intranasal H -antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. CONCLUSIONS: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.
[Mh] Termos MeSH primário: Antialérgicos/uso terapêutico
Asma/prevenção & controle
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Criança
Tomada de Decisão Clínica
Prática Clínica Baseada em Evidências
Seres Humanos
Qualidade de Vida
Rinite Alérgica/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Histamine H1 Antagonists)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE


  6 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28601540
[Au] Autor:Rojas-Perez-Ezquerra P; Noguerado-Mellado B; Morales-Cabeza C; Zambrano Ibarra G; Datino Romaniega T
[Ad] Endereço:Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Electronic address: patricia.rojas@salud.madrid.org.
[Ti] Título:Atrial Fibrillation in Anaphylaxis.
[So] Source:Am J Med;130(9):1114-1116, 2017 Sep.
[Is] ISSN:1555-7162
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The relationship between anaphylaxis and cardiovascular events has been reported in the past. While skin and respiratory symptoms are usually the most common and the first to appear, cardiovascular complications play a key role and represent the leading cause of death in anaphylaxis. METHODS: We report 3 episodes of atrial fibrillation triggered by anaphylaxis. Allergy and cardiology studies were performed. In both patients, the etiological agent was identified: Anisakis simplex hypersensitivity and food allergy. RESULTS: The heart is the source and target of chemical mediators released during an allergic reaction. In the heart, there are plenty of mast cells, and they are predominantly located around the coronary adventitia and in close contact with small vessels in the muscle wall. The release of mediators can influence ventricular function, heart rate, and coronary artery tone. Anaphylaxis can trigger any kind of arrhythmia. In these cases, the very interesting point of discussion was: which should be first, treating anaphylaxis or cardiac events? The other controversial point was the use of epinephrine, the first line of treatment for anaphylaxis. Recommendations about epinephrine in cardiac patients during an anaphylactic event are still a major dilemma. CONCLUSIONS: We emphasize the importance of the priority of establishing protocols between cardiologist and allergist in treatment of cardiac complications during anaphylaxis, and we warn about the correct diagnosis of arrhythmias in anaphylaxis in order to treat them as soon as possible, to prevent other consequences and complications.
[Mh] Termos MeSH primário: Anafilaxia/complicações
Atenolol/administração & dosagem
Fibrilação Atrial/etiologia
Clorfeniramina/administração & dosagem
Epinefrina/uso terapêutico
Hipersensibilidade Alimentar/complicações
Metilprednisolona/uso terapêutico
Urticária/complicações
[Mh] Termos MeSH secundário: Actinidia/efeitos adversos
Actinidia/imunologia
Administração Intravenosa
Adulto
Idoso de 80 Anos ou mais
Anafilaxia/tratamento farmacológico
Anafilaxia/etiologia
Animais
Anisakis/imunologia
Anisakis/parasitologia
Antiarrítmicos/administração & dosagem
Antiarrítmicos/imunologia
Antiarrítmicos/uso terapêutico
Anti-Inflamatórios/administração & dosagem
Anti-Inflamatórios/uso terapêutico
Arachis/efeitos adversos
Arachis/imunologia
Atenolol/imunologia
Atenolol/uso terapêutico
Fibrilação Atrial/tratamento farmacológico
Broncodilatadores/administração & dosagem
Broncodilatadores/uso terapêutico
Clorfeniramina/uso terapêutico
Quimioterapia Combinada
Epinefrina/administração & dosagem
Hipersensibilidade Alimentar/diagnóstico
Hipersensibilidade Alimentar/tratamento farmacológico
Hipersensibilidade Alimentar/etiologia
Gadiformes/imunologia
Gadiformes/parasitologia
Antagonistas dos Receptores Histamínicos H1/administração & dosagem
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Seres Humanos
Hipodermóclise
Masculino
Metilprednisolona/administração & dosagem
Urticária/etiologia
Urticária/imunologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); 0 (Anti-Inflammatory Agents); 0 (Bronchodilator Agents); 0 (Histamine H1 Antagonists); 3Q9Q0B929N (dexchlorpheniramine); 3U6IO1965U (Chlorpheniramine); 50VV3VW0TI (Atenolol); X4W7ZR7023 (Methylprednisolone); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170612
[St] Status:MEDLINE


  7 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28436624
[Au] Autor:Zhang L; Chen G; Chen J; He X; Hu X
[Ad] Endereço:Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
[Ti] Título:[Mechanisms of histamine ameliorating memory impairment induced by pentylenetetrazole-kindling epilepsy in rats].
[So] Source:Zhejiang Da Xue Xue Bao Yi Xue Ban;46(1):1-6, 2017 Jan 25.
[Is] ISSN:1008-9292
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the effects of neuronal histamine on spatial memory acquisition impairment in rats with pentylenetetrazole-kindling epilepsy, and to explore its mechanisms. A subconvulsive dose of pentylenetetrazole (35 mg/kg) was intraperitoneally injected in rats every 48 h to induce chemical kindling until fully kindled. Morris water maze was used to measure the spatial memory acquisition of the rats one week after fully pentylenetetrazole-kindled, and the histamine contents in different brain areas were measured spectrofluorometrically. Different dosages of hitidine (the precursor of histamine), pyrilamine (H1 receptor antagonist), and zolantidine (H2 receptor antagonist) were intraperitoneally injected, and their effects on spatial memory acquisition of the rats were observed. Compared with control group, escape latencies were significantly prolonged on Morris water maze training day 2 and day 3 in pentylenetetrazole-kindling epilepsy rats (all <0.05); and the histamine contents in hippocampus, thalamus and hypothalamus were decreased significantly (all <0.05). Escape latencies were markedly shortened on day 3 by intraperitoneally injected with histidine 500 mg/kg, and on day 2 and day 3 by intraperitoneally injected with histidine 1000 mg/kg in pentylenetetrazole-kindling epilepsy rats (all <0.05). The protection of histidine was reversed by zolantidine (10 and 20 mg/kg), but not by pyrilamine. Neuronal histamine can improve the spatial memory acquisition impairment in rats with pentylenetetrazole-kindling epilepsy, and the activation of H2 receptors is possibly involved in the protective effects of histamine.
[Mh] Termos MeSH primário: Transtornos da Memória/tratamento farmacológico
Receptores Histamínicos H2/efeitos dos fármacos
Receptores Histamínicos H2/fisiologia
Memória Espacial/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Benzotiazóis/farmacologia
Química Encefálica/efeitos dos fármacos
Epilepsia/induzido quimicamente
Epilepsia/complicações
Hipocampo/química
Antagonistas dos Receptores Histamínicos H1/farmacologia
Antagonistas dos Receptores Histamínicos H2/farmacologia
Histidina/farmacologia
Hipotálamo/química
Excitação Neurológica/fisiologia
Transtornos da Memória/etiologia
Pentilenotetrazol
Fenoxipropanolaminas/farmacologia
Piperidinas/farmacologia
Pirilamina/farmacologia
Ratos
Ratos Sprague-Dawley
Espectrometria de Fluorescência
Tálamo/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzothiazoles); 0 (Histamine H1 Antagonists); 0 (Histamine H2 Antagonists); 0 (Phenoxypropanolamines); 0 (Piperidines); 0 (Receptors, Histamine H2); 4QD397987E (Histidine); HPE317O9TL (Pyrilamine); M1108XAY01 (zolantidine); WM5Z385K7T (Pentylenetetrazole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170425
[St] Status:MEDLINE


  8 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28250021
[Au] Autor:Finlin BS; Zhu B; Confides AL; Westgate PM; Harfmann BD; Dupont-Versteegden EE; Kern PA
[Ad] Endereço:Department of Medicine, Division of Endocrinology, and the Barnstable Brown Diabetes and Obesity Center, University of Kentucky, Lexington, KY.
[Ti] Título:Mast Cells Promote Seasonal White Adipose Beiging in Humans.
[So] Source:Diabetes;66(5):1237-1246, 2017 May.
[Is] ISSN:1939-327X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human subcutaneous (SC) white adipose tissue (WAT) increases the expression of beige adipocyte genes in the winter. Studies in rodents suggest that a number of immune mediators are important in the beiging response. We studied the seasonal beiging response in SC WAT from lean humans. We measured the gene expression of various immune cell markers and performed multivariate analysis of the gene expression data to identify genes that predict UCP1. Interleukin (IL)-4 and, unexpectedly, the mast cell marker CPA3 predicted UCP1 gene expression. Therefore, we investigated the effects of mast cells on UCP1 induction by adipocytes. TIB64 mast cells responded to cold by releasing histamine and IL-4, and this medium stimulated UCP1 expression and lipolysis by 3T3-L1 adipocytes. Pharmacological block of mast cell degranulation potently inhibited histamine release by mast cells and inhibited adipocyte UCP1 mRNA induction by conditioned medium (CM). Consistently, the histamine receptor antagonist chlorpheniramine potently inhibited adipocyte UCP1 mRNA induction by mast cell CM. Together, these data show that mast cells sense colder temperatures, release factors that promote UCP1 expression, and are an important immune cell type in the beiging response of WAT.
[Mh] Termos MeSH primário: Adipócitos/metabolismo
Tecido Adiposo Bege/metabolismo
Tecido Adiposo Branco/metabolismo
Mastócitos/metabolismo
RNA Mensageiro/metabolismo
Estações do Ano
Proteína Desacopladora 1/genética
[Mh] Termos MeSH secundário: Células 3T3-L1
Adipócitos/efeitos dos fármacos
Adulto
Animais
Carboxipeptidases A/genética
Degranulação Celular
Clorfeniramina/farmacologia
Temperatura Baixa
Feminino
Regulação da Expressão Gênica
Histamina/metabolismo
Antagonistas dos Receptores Histamínicos H1/farmacologia
Seres Humanos
Interleucina-4/genética
Interleucina-4/metabolismo
Lipólise
Masculino
Proteínas de Membrana/genética
Camundongos
Análise Multivariada
Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/genética
RNA Mensageiro/efeitos dos fármacos
Reação em Cadeia da Polimerase em Tempo Real
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Gordura Subcutânea/metabolismo
Coxa da Perna
Proteína Desacopladora 1/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H1 Antagonists); 0 (IL4 protein, human); 0 (Membrane Proteins); 0 (PPARGC1A protein, human); 0 (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha); 0 (RNA, Messenger); 0 (TMEM26 protein, human); 0 (UCP1 protein, human); 0 (Ucp1 protein, mouse); 0 (Uncoupling Protein 1); 207137-56-2 (Interleukin-4); 3U6IO1965U (Chlorpheniramine); 820484N8I3 (Histamine); EC 3.4.17.1 (CPA3 protein, human); EC 3.4.17.1 (Carboxypeptidases A)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170818
[Lr] Data última revisão:
170818
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE
[do] DOI:10.2337/db16-1057


  9 / 11639 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28232472
[Au] Autor:Camilleri M; Boeckxstaens G
[Ad] Endereço:Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA.
[Ti] Título:Dietary and pharmacological treatment of abdominal pain in IBS.
[So] Source:Gut;66(5):966-974, 2017 May.
[Is] ISSN:1468-3288
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain in functional GI diseases, principally IBS. These approaches include dietary measures including fibre supplementation, low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet, and pharmacological approaches such as antispasmodics, peppermint oil, antidepressants (tricyclic agents, selective serotonin reuptake inhibitors), 5-HT receptor antagonists (alosetron, ondansetron, ramosetron), non-absorbed antibiotic (rifaximin), secretagogues (lubiprostone, linaclotide), µ-opioid receptor (OR) and κ-OR agonist, δ-OR antagonist (eluxadoline), histamine H1 receptor antagonist (ebastine), neurokinin-2 receptor antagonist (ibodutant) and GABAergic agents (gabapentin and pregabalin). Efficacy and safety are discussed based on pivotal trials or published systematic reviews and meta-analysis, expressing ORs or relative risks and their 95% CIs. Potential new approaches may be based on recent insights on mucosal expression of genes, and microRNA and epigenetic markers in human biopsies and in animal models of visceral hypersensitivity.The objectives of this review are to appraise the physiology and anatomy of gut sensation and the efficacy in the relief of visceral pain (typically in IBS) of several classes of therapies. These include fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and different classes of medications (box 1). Box 1Classes of pharmacological agents for visceral painAntidepressants (tricyclic agents, selective serotonin reuptake inhibitors)Peppermint oil5-HT receptor antagonists (alosetron, ondansetron, ramosetron)Non-absorbed antibiotic (rifaximin)Secretagogues (lubiprostone, linaclotide)µ-Opioid receptor (OR) and κ-OR agonist and δ-OR antagonist (eluxadoline)Histamine H1 receptor antagonist (ebastine)Neurokinin-2 receptor antagonist (ibodutant)GABAergic agents (gabapentin and pregabalin).
[Mh] Termos MeSH primário: Dor Abdominal/dietoterapia
Dor Abdominal/tratamento farmacológico
Síndrome do Intestino Irritável/complicações
Dor Visceral/dietoterapia
Dor Visceral/tratamento farmacológico
[Mh] Termos MeSH secundário: Dor Abdominal/etiologia
Anti-Infecciosos/uso terapêutico
Antidepressivos/uso terapêutico
Butirofenonas/uso terapêutico
Dipeptídeos/uso terapêutico
GABAérgicos/uso terapêutico
Fármacos Gastrointestinais/uso terapêutico
Antagonistas dos Receptores Histamínicos H1/uso terapêutico
Seres Humanos
Imidazóis/uso terapêutico
Parassimpatolíticos/uso terapêutico
Fenilalanina/análogos & derivados
Fenilalanina/uso terapêutico
Piperidinas/uso terapêutico
Óleos Vegetais/uso terapêutico
Probióticos/uso terapêutico
Compostos de Amônio Quaternário/uso terapêutico
Rifamicinas/uso terapêutico
Antagonistas do Receptor 5-HT3 de Serotonina/uso terapêutico
Tiofenos/uso terapêutico
Dor Visceral/etiologia
Dor Visceral/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Antidepressive Agents); 0 (Butyrophenones); 0 (Dipeptides); 0 (GABA Agents); 0 (Gastrointestinal Agents); 0 (Histamine H1 Antagonists); 0 (Imidazoles); 0 (Parasympatholytics); 0 (Piperidines); 0 (Plant Oils); 0 (Quaternary Ammonium Compounds); 0 (Rifamycins); 0 (Serotonin 5-HT3 Receptor Antagonists); 0 (Thiophenes); 1H7RSQ28BJ (ibodutant); 26095-59-0 (octylonium); 45TPJ4MBQ1 (eluxadoline); 47E5O17Y3R (Phenylalanine); AV092KU4JH (peppermint oil); L36O5T016N (rifaximin); TQD7Q784P1 (ebastine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170225
[St] Status:MEDLINE
[do] DOI:10.1136/gutjnl-2016-313425


  10 / 11639 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28190755
[Au] Autor:Kanamitsu K; Nozaki Y; Nagaya Y; Sugiyama Y; Kusuhara H
[Ad] Endereço:Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan; Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima-shi, Tokushima, 771-0192, Japan.
[Ti] Título:Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data.
[So] Source:Drug Metab Pharmacokinet;32(2):135-144, 2017 Apr.
[Is] ISSN:1880-0920
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Significant histamine H1 receptor occupation in the central nervous system (CNS) is associated with sedation. Here we examined the time profiles of the H1 receptor occupancy (RO) in the CNS using sedative (diphenhydramine and ketotifen) and non-sedative (bepotastine and olopatadine) antagonists at their therapeutic doses by integrating in vitro and animal data. A pharmacokinetic model was constructed to associate plasma concentrations and receptor binding in the brain. Dissociation and association rate constants with the H1 receptor and plasma and brain unbound fractions were determined in vitro. Passive and active clearances across the blood-brain barrier (BBB) were estimated based on physicochemical properties and microdialysis studies in mice and monkeys. The estimated RO values were comparable with the reported values determined at time to maximum concentration (T ) of plasma by positron-emission tomography in humans. The simulation suggested that the predicted maximum ROs by bepotastine and olopatadine were greater than the reported values. Sensitivity analysis showed that active transport across BBB had a significant impact on the RO duration of the H1 antagonists examined. The present study demonstrated that modeling and simulation permits a reasonable RO estimation in the human CNS. Our findings will facilitate the development of CNS-acting drugs.
[Mh] Termos MeSH primário: Sistema Nervoso Central/efeitos dos fármacos
Antagonistas dos Receptores Histamínicos H1/farmacologia
Receptores Histamínicos H1/metabolismo
[Mh] Termos MeSH secundário: Animais
Encéfalo/metabolismo
Sistema Nervoso Central/metabolismo
Difenidramina/sangue
Difenidramina/farmacologia
Antagonistas dos Receptores Histamínicos H1/sangue
Seres Humanos
Cetotifeno/sangue
Cetotifeno/farmacologia
Macaca fascicularis
Masculino
Camundongos
Camundongos Endogâmicos
Cloridrato de Olopatadina/sangue
Cloridrato de Olopatadina/farmacologia
Piperidinas/sangue
Piperidinas/farmacologia
Tomografia por Emissão de Pósitrons
Piridinas/sangue
Piridinas/farmacologia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histamine H1 Antagonists); 0 (Piperidines); 0 (Pyridines); 0 (Receptors, Histamine H1); 2XG66W44KF (Olopatadine Hydrochloride); 8GTS82S83M (Diphenhydramine); HYD2U48IAS (bepotastine); X49220T18G (Ketotifen)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170505
[Lr] Data última revisão:
170505
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170214
[St] Status:MEDLINE



página 1 de 1164 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde